Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Säkerhet och effekt av Ponatinib för behandling av återkommande eller refraktära leukemier, lymfom eller solida tumörer hos barn

12 november 2026 uppdaterad av: Incyte Biosciences International Sàrl

En öppen, enarmad, fas 1/2-studie som utvärderar säkerheten och effekten av Ponatinib för behandling av återkommande eller refraktära leukemier, lymfom eller solida tumörer hos pediatriska deltagare

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

70

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Ghent, Belgien, 09000
        • Rekrytering
        • Ghent University Hospital
      • Paris, Frankrike, 75019
        • Rekrytering
        • Hopital Robert Debre
      • Paris, Frankrike, 75571
        • Rekrytering
        • Armand Trousseau Hospital
      • Poitiers, Frankrike, 86021
        • Rekrytering
        • Centre Hospitalier Universitaire de Poitiers
      • Rennes, Frankrike, 35203
        • Avslutad
        • Chu de Rennes - Hospital Sud
      • Bologna, Italien, 40138
        • Rekrytering
        • Aou Policlinico S. Orsola-Malpighi
      • Brescia, Italien, 25123
        • Rekrytering
        • Asst Degli Spedali Civili Di Brescia
      • Genova, Italien, 16147
        • Rekrytering
        • Ospedale Pediatrico G. Gaslini
      • Milan, Italien, 20133
        • Rekrytering
        • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
      • Monza, Italien, 20900
        • Rekrytering
        • University of Milano Bicocca
      • Naples, Italien, 80123
        • Rekrytering
        • Aorn Santobono Pausilipon
      • Pavia, Italien, 27100
        • Rekrytering
        • Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
      • Rome, Italien, 00165
        • Rekrytering
        • Ospedale Pediatrico Bambino Gesu Irccs
      • Torino, Italien, 10126
        • Rekrytering
        • A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita
      • Utrecht, Nederländerna, 03584
        • Rekrytering
        • Princess Maxima Center For Pediatric Oncology
      • Barcelona, Spanien, 08035
        • Rekrytering
        • Hospital General Universitario Vall D Hebron
      • Barcelona, Spanien, 08035
        • Rekrytering
        • Hospital Sant Joan de Deu de Manresa
      • Madrid, Spanien, 28009
        • Rekrytering
        • Hospital Infantil Unversitario Nino Jesus
      • Valencia, Spanien, 46026
        • Rekrytering
        • Hospital Universitari I Politecnic La Fe
      • Glasgow, Storbritannien, G514TF
        • Rekrytering
        • Royal Hospital For Sick Children Yorkhill Glasgow
      • Liverpool, Storbritannien, L12 2AP
        • Rekrytering
        • Alder Hey Childrens Nhs Foundation Trust
      • Sutton, Storbritannien, SM2 5PT
        • Rekrytering
        • The Royal Marsden Nhs Foundation Trust - Sutton
      • Stockholm, Sverige, 14141
        • Rekrytering
        • Karolinska University Hospital Solna

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 år till 17 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of the following malignancies:

- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, for which standard therapy is not available or is not indicated.

- Phase 2, Group A with CP-CML: CP-CML at the time of study entry and must be resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy or be in "warning" response status or have the T315I kinase domain mutation.

Must have 1 bone marrow aspirate with documentation of BCR-ABL translocation by conventional cytogenetics, metaphase FISH, or q-PCR performed within 42 days before the first dose of ponatinib.

- Phase 2, Group B with other leukemias or solid tumors: ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, with mutations of RET, FLT3, KIT, FGFR, PDGFR, TIE2, VEGFR, or any other mutations where ponatinib may have biological activity (eg, EPH receptors and SRC families of kinases) as assessed on fresh or archived tumor tissue.

Participants with solid tumors or with lymphoma must have measurable disease by CT or MRI based on RECIST v1.1 or the Lugano lymphoma guidelines as determined by site radiology.

Prior therapies as follows:

- Phase 1: Participants with CML who are resistant to or intolerant of (as defined Appendix F) to at least 1 prior BCR-ABL-targeted TKI therapy.

Participants with ALL who have progressed on or after all available or indicated therapies, which may have included 1 prior BCR-ABL-targeted TKI therapy.

Participants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).

Participants with solid tumors (including tumors of the CNS) or lymphomas who have progressed despite standard therapy or for whom no effective standard therapy is available or indicated.

- Phase 2, Group A with CP-CML: Participants who are resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy.

- Phase 2, Group B with other leukemias or solid tumors: Participants with ALL who have progressed on or after all available or indicated therapies, which must have included 1 prior BCR-ABL-targeted TKI therapy.

Participants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).

Participants with solid tumors (including tumors of the CNS) or lymphomas who progressed despite standard therapy or for whom no effective standard therapy is available or indicated.

  • Karnofsky performance status ≥ 40% for participants ≥ 16 years old or Lansky Play Scale ≥ 40% for pediatric participants < 16 years old.
  • Participants must have recovered to < Grade 2 per the NCI CTCAE v5.0 or to baseline from any non-hematologic toxicities (except alopecia) due to previous therapy.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

Prior therapies:

- Participants with BP-CML, ALL, or AML who have received any of the following: Corticosteroids or hydroxyurea within 24 hours before the first dose of ponatinib.

Vincristine within 7 days before the first dose of ponatinib. Other chemotherapy (excluding intrathecal chemotherapy) within 14 days before the first dose of ponatinib.

- Participants (except the BP-CML, ALL, and AML participants described above) who: Have had cytotoxic chemotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) before the first dose of ponatinib.

Prior radiation therapy or radio-isotope therapy within 6 weeks before the first dose of ponatinib except local radiotherapy for palliative indication within 14 days before the first dose of ponatinib.

Autologous or allogeneic stem cell transplant < 3 months before the first dose of ponatinib.

Major surgery within 14 days before the first dose of ponatinib. Inadequate recovery and/or complications from a major surgery before starting therapy.

Prior treatment with any of the following:

  • Immunosuppressive therapy (including post stem cell transplant regimens) within 14 days before the first dose of ponatinib.
  • Any targeted cancer therapy (including TKIs) within 7 days before the first dose of ponatinib.
  • Any other investigational anticancer agents within 30 days or 5 half-lives, whichever is longer, before randomization.
  • Any monoclonal antibody-directed anticancer therapy within 5 half-lives of the first dose of ponatinib.
  • Any chimeric antigen receptor therapy within 28 days before the first dose of ponatinib
  • Ponatinib
  • Protocol-defined lab Values
  • Significant concurrent, uncontrolled medical condition, including but not limited to the following:
  • Pancreatic: clinical, radiological, or laboratory evidence of pancreatitis.
  • Cardiac:
  • SF < 27% by ECHO, OR EF < 50% by MUGA.
  • Abnormal QTcF on screening ECG, defined as QTcF of ≥ 450 ms.
  • Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute MI within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV CHF (see Appendix P), and arrhythmia requiring therapy unless approved by the medical monitor/sponsor.
  • Uncontrolled hypertension.
  • Currently taking drug(s) that are known to have a risk of causing prolonged QTc or TdP unless the drug(s) can be changed to acceptable alternatives (ie, an alternate class of agents that do not affect the cardiac conduction system), or the participant can safely discontinue the drug(s).
  • Cerebral:
  • Participants with solid tumors with intracranial metastasis OR participants with active CNS leukemia (ie, CNS-2 status [< 5/μL WBCs and cytospin positive for blasts, or ≥ 5 /μL WBCs but negative by Steinherz/Bleyer algorithm (equation used for traumatic lumbar punctures), disseminated leptomeningeal disease, or CNS chloroma.
  • Pre-existing significant CNS pathology including history of severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination/movement disorder, or autoimmune disease with CNS involvement.
  • History of cerebrovascular ischemia/hemorrhage with residual deficits.
  • Note: Participants with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved clinically according to Inclusion Criterion 6.
  • Uncontrolled seizure disorder.
  • Coagulation:
  • Significant bleeding disorder or thrombophilia unrelated to the underlying malignancy indication for study participation.
  • Gastrointestinal:
  • Gastrointestinal disorders, such as malabsorption syndrome or any other illness that could affect oral absorption.
  • Genetic:
  • Participants with DNA fragility syndromes, such as Fanconi anemia and Bloom syndrome.
  • Participants with Down syndrome.
  • Participants with any active ≥ Grade 2 graft versus host disease.
  • Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
  • Active HBV or HCV infection that requires treatment or at risk for HBV reactivation. Hepatitis B virus DNA and HCV RNA must be undetectable upon testing. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive.
  • Known HIV infection.
  • Current use of prohibited medication (see Section 6.7.2).
  • Known hypersensitivity or severe reaction to ponatinib or excipients of ponatinib.
  • Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.
  • Inability or unlikeliness to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  • Females who are pregnant or lactating.
  • Other exclusions may apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Ponatinib

Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.

Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.

Andra namn:
  • Iclusig, INCB84344

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fas 2: Effekten av ponatinib utvärderad genom fullständig respons (CR) hos deltagare med andra leukemier än BCR-ABL-positiva leukemier för att bestämma effekten av ponatinib
Tidsram: 6 månader
6 månader
Phase 1: Number of dose-limiting toxicities
Tidsram: 28 days

Defined as the occurrence of any protocol-defined toxicities occurring after dosing and up to and including Day 28, except those toxicities with a clear alternative explanation.

28 days
Phase 2: Efficacy of ponatinib assessed by major cytogenetic response (MCyR) in participants with chronic-phase chronic myeloid leukemia (CP-CML)
Tidsram: 12 months

Defined as complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) as assessed by conventional cytogenetics or fluorescence in situ hybridization (FISH).

12 months
Phase 2: Efficacy of ponatinib assessed by major hematologic response (MaHR) or major molecular response (MMR) in participants with BCR-ABL-positive leukemias
Tidsram: 3 months

Assessed by polymerase chain reaction (PCR).

3 months
Phase 2: Efficacy of ponatinib assessed by incomplete complete response (iCR) in participants with leukemias other than BCR-ABL-positive leukemias
Tidsram: 6 months

Assessed by conventional cytogenetics, FISH, or PCR.

6 months
Phase 2: Efficacy of ponatinib assessed by CR in participants with lymphoma
Tidsram: 6 months

According to Lugano criteria based on computed tomography (CT) or magnetic resonance imaging (MRI) (or positron emission tomography [PET]).

6 months
Phase 2: Efficacy of ponatinib assessed by overall response rate in participants with solid tumors
Tidsram: 6 months

Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for central nervous system (CNS) tumors or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for other solid tumors based on CT or MRI (or PET).

6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fas 1: Antal behandlingsuppkomna biverkningar
Tidsram: 6 månader
6 månader
Fas 1 och Fas 2: Komplett hematologisk respons (CHR) hos deltagare med CP-CML
Tidsram: 6 månader
6 månader
Fas 1 och Fas 2: CCyR hos deltagare med CP-CML
Tidsram: 12 månader
12 månader
Fas 1 och Fas 2: MMR hos deltagare med CP-CML
Tidsram: 12 månader
12 månader
Fas 1: CR hos deltagare med andra leukemier än BCR-ABL-positiv leukemi eller CP-CML.
Tidsram: 6 månader
6 månader
Fas 2: Anticanceraktivitet av ponatinib utvärderad med MaHR eller MMR hos deltagare med BCR-ABL-positiva leukemier (AP-CML, BP-CML eller Ph+ALL)
Tidsram: 3 månader
3 månader
Fas 2: Anticanceraktivitet av ponatinib utvärderad av CR hos deltagare med andra leukemier än BCR-ABL-positiva leukemier
Tidsram: 6 månader
6 månader
Fas 2: Antal behandlingsuppkomna biverkningar
Tidsram: 6 månader
6 månader
Fas 2: Clearance av pediatriskt vänlig formulering av ponatinib
Tidsram: 6 månader
6 månader
Fas 2: Distributionsvolym av pediatriskt vänlig formulering av ponatinib
Tidsram: 6 månader
6 månader
Fas 2: AUC för pediatriskt vänlig formulering av ponatinib
Tidsram: 6 månader
6 månader
Phase 1: Tmax of ponatinib
Tidsram: 6 months

Time to maximum concentration.

6 months
Phase 1: AUCss,0-24 of ponatinib
Tidsram: 6 months

Area under the steady-state plasma or serum concentration-time curve from Hour 0 to 24.

6 months
Phase 1: t½ of ponatinib
Tidsram: 6 months

Apparent terminal-phase disposition half-life.

6 months
Phase 1: CLss/F of ponatinib
Tidsram: 6 months

Apparent oral dose clearance at steady state.

6 months
Phase 1: Vz/F of ponatinib
Tidsram: 6 months

Apparent oral dose volume of distribution.

6 months
Phase 1: MCyR in participants with BCR-ABL-positive leukemias
Tidsram: 3 months

Defined as CCyR or PCyR as assessed by conventional cytogenetics or FISH.

3 months
Phase 1: MMR in participants with BCR-ABL-positive leukemias
Tidsram: 3 months

Assessed by quantitative PCR (q-PCR).

3 months
Phase 1 and Phase 2: Time to response (TTR) in participants with CP-CML
Tidsram: 6 months

Defined as the interval from the date of the first dose of study treatment to first response.

6 months
Phase 1 and Phase 2: Duration of response (DOR) in participants with CP-CML
Tidsram: 6 months

Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met.

6 months
Phase 1 and Phase 2: Progression-free survival (PFS) in participants with CP-CML
Tidsram: 6 months

Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier.

6 months
Phase 1 and Phase 2: Overall survival (OS) in participants with CP-CML
Tidsram: 6 months

Defined as the interval from the date of the first dose of study treatment until death from any cause.

6 months
Phase 1: CRi in participants with leukemias other than BCR-ABL-positive leukemia or CP-CML
Tidsram: 6 months

Assessed by conventional cytogenetics, FISH, or q-PCR.

6 months
Phase 1: CR in participants with lymphoma
Tidsram: 6 months

According to Lugano criteria based on CT or MRI (or PET).

6 months
Phase 1: Overall response rate in participants with solid tumors
Tidsram: 6 months

Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET).

6 months
Phase 2: Anticancer activity of ponatinib assessed by CRi in participants with leukemias other than BCR-ABL-positive leukemias.
Tidsram: 6 months

Assessed by conventional cytogenetics, FISH, or PCR.

6 months
Phase 2: Anticancer activity of ponatinib assessed by CR in participants with lymphoma
Tidsram: 6 months

According to Lugano criteria based on CT or MRI (or PET).

6 months
Phase 2: Anticancer activity of ponatinib assessed by overall response rate in participants with solid tumors
Tidsram: 6 months

Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET).

6 months
Phase 2: OS in participants with solid tumors
Tidsram: 6 months

Defined as the interval from the date of the first dose of study treatment until death from any cause.

6 months
Phase 2: DOR in participants with solid tumors
Tidsram: 6 months

Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met.

6 months
Phase 2: PFS in participants with solid tumors
Tidsram: 6 months

Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier.

6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Mohammed-El-Amine Bensmaine, MD, Incyte Biosciences International Sàrl

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 januari 2020

Primärt slutförande (Beräknad)

1 februari 2028

Avslutad studie (Beräknad)

1 februari 2028

Studieregistreringsdatum

Först inskickad

29 april 2019

Först inskickad som uppfyllde QC-kriterierna

29 april 2019

Första postat (Faktisk)

1 maj 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera